SLC5A2 and chronic kidney disease: Additional data revealed the beneficial therapeutic effects of SGLT2 inhibitor treatment in people with chronic kidney disease (CKD) to delay disease progression and improve cardiovascular benefits [28,29], as well as additional positive effects of SGLT2 inhibitor treatment due to modest reductions in blood pressure and bodyweight [24,25,28].